CPDD Statement on Psychedelics: Cautions and Support for More Investment in Psychedelic Research CPDD supports expanded federal and private sector investments in clinical studies examining the potential of psychedelic and dissociative medications for the treatment of psychiatric conditions. CPDD cautions against premature and/or hyperbolic misinterpretation of the careful, but limited, clinical research knowledge base as currently indicating quick fixes for...
Read More